Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

The EGF receptor family as targets for cancer therapy

Abstract

Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been associated with a more aggressive clinical behavior. Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype. For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments. In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed. These MAbs have shown promising preclinical activity and ‘chimeric’ and ‘humanized’ MAbs have been produced in order to obviate the problem of host immune reactions. Clinical activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC-C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy. In addition to antibodies, compounds that directly inhibit receptor tyrosine kinases have shown preclinical activity and early clinical activity has been reported. A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and will further address the role of these active anti-receptor agents in the treatment of patients with cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Abbreviations

MAb:

monoclonal antibody

EGFr:

epidermal growth factor receptor

TGF-α:

transforming growth factor alpha

HB-EGF:

heparin binding EGF

References

  • Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J and Sela M. . 1988 J. Natl. Cancer Inst. 80: 1605–1611.

  • Alroy I and Yarden Y. . 1997 FEBS Lett. 410: 83–86.

  • Arteaga CL, Carty-Dugger T and Winnier AR. . 1993 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 12: A103.

  • Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD and Stewart SJ. . 1994 Cancer Res. 54: 3758–3765.

  • Baly DL, Wirth CM, Allison DA, Gilkerson E, Hotaling TE and Fox JA. . 1997 Proc. Annu. Meet. Am. Assoc. Cancer Res. 38: 27.

  • Barnes D and Sato G. . 1980 Cell 22: 649–655.

  • Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A, Kaye SB, Kieback DG, Harris A and Ochs J. . 2000b Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 177a.

  • Baselga J and Mendelsohn J. . 1994 Pharmac. Therapeu. 64: 127–154.

  • Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J. . 1998 Cancer Res. 58: 2825–2831.

  • Baselga J, Norton L, Coplan K, Shalaby R and Mendelsohn J. . 1994 Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 380.

  • Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller Jr WH and Mendelsohn J. . 1993 J. Natl. Cancer Inst. 85: 1327–1333.

  • Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Anderson V, Waksal H and Mendelsohn J. . 2000a J. Clin. Oncol. 18: 904–914.

  • Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L. . 1996 J. Clin. Oncol. 14: 737–744.

  • Bonner JA, Ezekiel MP, Robert F, Meredith RF, Spencer SA and Waksal HW. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19:: 4a.

  • Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW and Baselga J. . 1997 Clin. Cancer Res. 3: 2099–2106.

  • Brennan P, Babbage JW, Burgering BM, Groner B, Reif K and Cantrell DA. . 1997 Immunity 7: 679–689.

  • Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ and Radinsky R. . 2000a Clin. Cancer Res. 6: 1936–1948.

  • Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R and Fidler IJ. . 2000b Cancer Res. 60: 2926–2935.

  • Budillon A, Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Pepe S, Tagliaferri P, Abbruzzese A, Caragllia M and Caponigro F. . 2000 Proc. Annu. Meet. Am. Assoc. Cancer Res. 41: 773.

  • Burden S and Yarden Y. . 1997 Neuron 18: 847–855.

  • Burgering BM and Coffer PJ. . 1995 Nature 376: 599–602.

  • Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK and Arteaga CL. . 2000 J. Biol. Chem. 275: 6987–6995.

  • Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC. . 1998 Science 282: 1318–1321.

  • Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM. . 1992 Proc. Natl. Acad. Sci. USA 89: 4285–4289.

  • Chan KC, Knox F, Woodburn WR, Slamon D, Potten CS and Bundred NJ. . 2000 Proc. Annu. Meet. Am. Assoc. Cancer Res. 41: 482.

  • Chan TO, Rittenhouse SE and Tsichlis PN. . 1999 Annu. Rev. Biochem. 68: 965–1014.

  • Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN and Rosenfeld MG. . 1987 Nature 328: 820–823.

  • Chinkers M and Cohen S. . 1981 Nature 290: 516–519.

  • Chou J-L, Fan Z, DeBlasio T, Koff A, Rosen N and Mendelsohn J. . 1999 Breast Cancer Res. Treat. 55: 267–283.

  • Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR and Tortora G. . 1999 Clin. Cancer Res. 5: 909–916.

  • Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G. . 2000 Clin. Cancer Res. 6: 2053–2063.

  • Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR and Tortora G. . 1996 J. Natl. Cancer Inst. 88: 1770–1776.

  • Clynes RA, Towers TL, Presta LG and Ravetch JV. . 2000 Nat. Med. 6: 443–446.

  • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ. . 1999 J. Clin. Oncol 17: 2639–2648.

  • Codony-Servat J, Albanell J, Arribas J and Baselga J. . 2000 Proc. Annu. Meet. Am. Assoc. Cancer Res. 41: 68.

  • Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J. . 1999 Cancer Res. 59: 1196–1201.

  • Cohen RB, Falcey JW, Paulter VJ, Fetzer KM and Waksal HW. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 474a.

  • Cohen S. . 1962 J. Biol. Chem. 237: 1555–1562.

  • Cohen S, Carpenter G and King Jr L. . 1980 J. Biol. Chem. 255: 4834–4842.

  • Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H and Lloveras B. . 2000 Clin. Cancer Res. 6: 2356–2362.

  • Cooper JA and Hunter T. . 1981 J. Cell. Biol. 91: 878–883.

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME. . 1997 Cell 91: 231–241.

  • DiFiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J and Aaronson SA. . 1987 Cell 51: 1063–1070.

  • Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM and Mendelsohn J. . 1991 J. Natl. Cancer Inst. 83: 97–104.

  • Drebin JA, Link VC, Stern DF, Weinberg RA and Greene MI. . 1985 Cell 41: 697–706.

  • Drebin JA, Link VC, Weinberg RA and Greene MI. . 1986 Proc. Natl. Acad. Sci. USA 83: 9129–9133.

  • Erickson E, Shealy DJ and Erickson RL. . 1981 J. Biol. Chem. 256: 11381–11384.

  • Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC. . 1992 Cell 69: 119–128.

  • Fan Z, Baselga J, Masui H and Mendelsohn J. . 1993 Cancer Res. 53: 4637–4642.

  • Fan Z, Lu Y, Wu X and Mendelsohn J. . 1994 J. Biol. Chem. 269: 27595–27602.

  • Fan Z, Shang BY, Lu Y, Chou J-L and Mendelsohn J. . 1997 Clin. Cancer Res. 3: 1943–1948.

  • Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA and Ullrich A. . 1990 Cancer Res. 50: 1550–1558.

  • Ferry D, Hammond L, Ranson M, Kris M, Miller V, Murray P, Tullo A, Feyereislova A, Averbuch S and Rowinsky E. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 3a.

  • Fong C-J, Sherwood ER, Mendelsohn J, Lee C and Kozlowski JM. . 1992 Cancer Res. 52: 5887–5892.

  • Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S and Dobrusin EM. . 1998 Proc. Natl. Acad. Sci. USA 95: 12022–12027.

  • Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW and Bridges AJ. . 1994 Science 265: 1093–1095.

  • Fry DW, Nelson JM, Slintak V, Keller PR, Rewcastle GW, Denny WA, Zhou H and Bridges AJ. . 1997 Biochem. Pharmacol. 54: 877–887.

  • Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C and Mendelsohn J. . 1984 J. Biol. Chem. 259: 7755–7760.

  • Goldstein NI, Prewett M, Zuklys K, Rockwell P and Mendelsohn J. . 1995 Clin. Cancer Res. 1: 1311–1318.

  • Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD and Muller WJ. . 1992 Proc. Natl. Acad. Sci. USA 89: 10578–10582.

  • Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver LK. . 1991 Cancer Res. 51: 4575–4580.

  • Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC and Yarden Y. . 1999 Oncogene 18: 2681–2689.

  • Harris LN, Trock B, Berris M, Esteva-Lorenzo F and Paik S. . 1996 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 15: 108.

  • Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H and Lewis GD. . 1992 Science 256: 1205–1210.

  • Huang SM, Bock JM and Harari PM. . 1999 Cancer Res. 59: 1935–1940.

  • Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM and Ullrich A. . 1989 Mol. Cell. Biol. 9: 1165–1172.

  • Hudziak RM, Schlessinger J and Ullrich A. . 1987 Proc. Natl. Acad. Sci. USA 84: 7159–7163.

  • Hynes NE and Stern DF. . 1994 Biochim. Biophys. Acta 1198: 165–184.

  • Karunagaran D, Tzahar E, Beerli R, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE and Yarden Y. . 1996 EMBO J. 15: 254–264.

  • Kasprzyk PG, Song SU, DiFiore PP and King CR. . 1992 Cancer Res. 52: 2771–2776.

  • Kawamoto T, Mendelsohn J, Le A, Sato GH, Lazar CS and Gill GN. . 1984 J. Biol. Chem. 259: 7761–7766.

  • Kawamoto TK, Sato JD, Le A, Polikoff J, Sato GH and Mendelsohn J. . 1983 Proc. Natl. Acad. Sci. USA 80: 1337–1341.

  • Kelly HC, Laight A, Morris CQ, Woodburn JR and Richmond GHP. . 1998 Ann. Oncol. 9: 419.

  • Khazaeli MB, LoBuglio AF, Falcey JW, Paulter VJ, Fetzer KM and Waksal HW. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 207a.

  • Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M and Yarden Y. . 1999 Proc. Natl. Acad. Sci. USA 96: 4995–5000.

  • Klapper LN, Kirschbaum MH, Sela M and Yarden Y. . 2000 Adv. Cancer Res. 77: 25–79.

  • Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y and Sela M. . 1997 Oncogene 14: 2099–2109.

  • Klohs WD, Fry DW and Kraker AJ. . 1997 Curr. Opin. Oncol. 9: 562–568.

  • Kumar R, Shepard HM and Mendelsohn J. . 1991 Mol. Cell. Biol. 11: 979–986.

  • Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM and Hynes NE. . 2000 Mol. Cell Biol. 20: 3210–3223.

  • Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L and Lipton A. . 1995 J. Clin. Oncol. 13: 1129–1135.

  • Lemmon MA and Schlessinger J. . 1994 Trends Biochem. Sci. 19: 459–463.

  • Levitzki A and Gazit A. . 1995 Science 267: 1782–1788.

  • Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C and Shepard HM. . 1993 Cancer Immunol. Immunother. 37: 255–263.

  • Lin CR, Chen WS, Kruiger W, Stolarsky LS, Weber W, Evans RM, Verma IM, Gill GN and Rosenfeld MG. . 1984 Science 224: 843–848.

  • Lipton A, Ali S, Leitzel K, Chinchilli V, Engle L, Demers L, Brady C, Carney W, Cook JB, Cambetas D and Allard J. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 71a.

  • Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J and Fan Z. . 2000 Br. J. Cancer 82: 1991–1999.

  • Liu W, Li J and Roth RA. . 1999 Biochem. Biophys. Res. Commun. 261: 897–903.

  • Lupu R, Colomer R, Kannan B and Lippman ME. . 1992 Proc. Natl. Acad. Sci. USA 89: 2287–2291.

  • Lydon NB, Mett H, Mueller M, Becker M, Cozens RM, Stover D, Daniels D, Traxler P and Buchdunger E. . 1998 Int. J. Cancer 76: 154–163.

  • Mandal M, Adam L, Mendelsohn J and Kumar R. . 1998 Oncogene 17: 999–1007.

  • Markowitz SD, Molkentin K, Gerbic C, Jackson J, Stellato T and Willson JKV. . 1990 J. Clin. Invest. 86: 356–362.

  • Masui H, Kawamoto T, Sato JD, Wolf B, Sato G and Mendelsohn J. . 1984 Cancer Res. 44: 1002–1007.

  • McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL and Carney WP. . 1989 Oncogene 4: 543–548.

  • Meikrantz W and Schlegel R. . 1995 J. Cell. Biochem. 58: 160–174.

  • Mendelsohn J. . 1997 Clin. Cancer Res. 3: 2703–2707.

  • Mendelsohn J. . 2000 Clin. Cancer Res. 6: 747–753.

  • Mendelsohn J and Baselga J. . 1995 Biologic Therapy of Cancer, 2nd Ed. DeVita Jr VT, Hellman S and Rosenberg SA (eds). JB Lippincott Co.: Philadelphia, PA pp. 607–623.

  • Mendelsohn J, Shin DM, Donato N, Khuri F, Radinsky R, Glisson BS, Shin HJ, Metz E, Pfister D, Perez-Soler R, Lawhorn K, Matsumoto T, Gunnett K, Falcey J, Waksal H and Hong WK. . 1999 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: 389a.

  • Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J and Fan Z. . 2000 Clin. Cancer Res. 6: 701–706.

  • Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C and Gore M. . 1996 Br. J. Cancer 73: 228–235.

  • Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A and Miller P. . 1997 Cancer Res. 57: 4838–4848.

  • Muthuswamy SK, Gilman M and Brugge JS. . 1999 Mol. Cell Biol. 19: 6845–6857.

  • Nakagawa K, Yamamoto N, Kudoh S, Negoro S, Takeda K, Tamura T and Fukuoka M. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 183a.

  • Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M and Shak S. . 1999 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: 127a.

  • Olayioye MA, Neve RM, Lane HA and Hynes NE. . 2000 EMBO J. 19: 3159–3167.

  • Pardee AB. . 1989 Science 246: 603–608.

  • Pawson T and Schlessinger J. . 1994 Curr. Biol. 3: 434–442.

  • Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F and Slamon D. . 1999 Oncogene 18: 2241–2251.

  • Pegram MD, Baly D, Wirth C, Gilkerson E, Slamon D, Sliwkowski MX, Bauer K and Fox JA. . 1997a Proc. Annu. Meet. Am. Assoc. Cancer Res. 38: 602.

  • Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ and Slamon DJ. . 1997b Oncogene 15: 537–547.

  • Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ. . 1998 J. Clin. Oncol. 16: 2659–2671.

  • Peng D, Fan Z, Lu Y, DeBlasio T, Scher H and Mendelsohn J. . 1996 Cancer Res. 56: 3666–3669.

  • Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang H-Z, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK and Murray JL. . 1994 J. Clin. Oncol. 12: 730–739.

  • Perez-Soler R, Shin DM, Donato N, Radinsky R, Khuri F, Glisson BS, Shin H, Matsumoto T, Lawhorn K, Waksal H, Hong WK and Mendelsohn J. . 1998 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 17: 393a.

  • Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R and Dinney CP. . 1999 Clin. Cancer Res. 5: 257–265.

  • Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B and Kerbel RS. . 1997 Am. J. Pathol. 151: 1523–1530.

  • Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB and Slamon DJ. . 1994 Oncogene 9: 1829–1838.

  • Pietras RJ, Pegram MD, Finn RS, Maneval DA and Slamon DJ. . 1998 Oncogene 17: 2235–2249.

  • Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ and Slamon DJ. . 1999 Cancer Res. 59: 1347–1355.

  • Reese D, Arboleda J, Twaddell J, Akita R, Sliwkowski MX and Slamon D. . 1996 Proc. Annu. Meet. Am. Assoc. Cancer Res. 37: 51.

  • Riese DJ and Stern DF. . 1998 Bioessays 20: 41–48.

  • Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z and Koprowski H. . 1987 Cancer Res. 47: 3692–3696.

  • Rubin MS, Shin DM, Pasmantier M, Falcey JW, Paulter VJ, Fetzer KM, Waksal HW, Mendelsohn J and Hong WK. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 474a.

  • Salomon DS, Brandt R, Ciardiello F and Normanno N. . 1995 Crit. Rev. Oncol. Hematol. 19: 183–232.

  • Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A and Shepard HM. . 1991 Growth Regul. 1: 72–82.

  • Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH. . 1983 Mol. Biol. Med. 1: 511–529.

  • Sepp-Lorenzino L, Bos M, Ma Z, Baselga J, Rands E, Kohl NE, Oliff A, Mendelsohn J and Rosen N. . 1996 Proc. Annu. Meet. Am. Assoc. Cancer Res. 37: 421.

  • Sirotnak FM, Zakowsky MF, Miller VA, Scher HI and Kris MG. . 2000 Proc. Annu. Meet. Am. Assoc. Cancer Res. 41: 482.

  • Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J and Norton L. . 1998 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 17: 98a.

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. . 1987 Science 235: 177–182.

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A. . 1989 Science 244: 707–712.

  • Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA. . 1999 Semin. Oncol. 26: 60–70.

  • Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL and Carraway KL3. . 1994 J. Biol. Chem. 269: 14661–14665.

  • Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW and Patmore SJ. . 1999 J. Med. Chem. 42: 1803–1815.

  • Sporn MB and Todaro GJ. . 1980 N. Engl. J. Med. 303: 878–880.

  • Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y and Sela M. . 1991 Proc. Natl. Acad. Sci. USA 88: 8691–8695.

  • Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, Tamaoki N, Tajima T and Mitomi T. . 1996 Br. J. Cancer 73: 1362–1365.

  • Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J and Ciardiello F. . 1999 Clin. Cancer Res. 5: 875–881.

  • Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A and Wen D. . 1994 J. Biol. Chem. 269: 25226–25233.

  • Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA and Schlessinger J. . 1984 Nature 309: 418–425.

  • Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H and Elliott WL. . 2000 Cancer Chemother. Pharmacol. 45: 231–238.

  • Vogel C, Cobleigh M, Tripathy D, Harris L, Fehrenbacher L, Slamon D, Ash M, Novotny W, Stewart S and Shak S. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 71a.

  • Waterfield MD, Mayes ELV, Stroobant P, Bennett PLP, Young S, Goodfellow PN, Banting GS and Ozanne B. . 1982 J. Cell. Biochem. 20: 149–161.

  • Woodburn JR, Barker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L and Henthorn LR. . 1997 Proc. Annu. Meet. Am. Assoc. Cancer Res. 38: 633.

  • Woodburn JR, Kendrew J, Fennell M and Wakeling AE. . 2000 Proc. Annu. Meet. Am. Assoc. Cancer Res. 41: 402.

  • Wu X, Fan Z, Masui H, Rosen N and Mendelsohn J. . 1995 J. Clin. Invest. 95: 1897–1905.

  • Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A and Mendelsohn J. . 1996 Oncogene 12: 1397–1403.

  • Xu YH, Ishii S, Clark AJ, Sullivan M, Wilson RK, Ma DP, Roe BA, Merlino GT and Pastan I. . 1984 Nature 309: 806–810.

  • Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG and Jakobovits A. . 1999 Cancer Res. 59: 1236–1243.

  • Yang X, Jia X, Corvalan JR, Wang P, Wu E, Zhang L and Davis CG. . 2000 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19: 48a.

  • Ye D, Mendelsohn J and Fan Z. . 1999 Oncogene 18: 731–738.

  • Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ and Hung MC. . 1998 Mol. Cell. 2: 581–591.

  • Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J and Godowski PJ. . 1997 Proc. Natl. Acad. Sci. USA 94: 9562–9567.

Download references

Acknowledgements

Dr Mendelsohn holds stock options in and is a director of ImClone Systems, Inc., New York, which is performing the clinical trials with IMC-C225.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mendelsohn, J., Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550–6565 (2000). https://doi.org/10.1038/sj.onc.1204082

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204082

Keywords

This article is cited by

Search

Quick links